Multiple Sclerosis
Conditions
Keywords
Multiple Sclerosis, Relapsing Multiple Sclerosis, Mavenclad, Cladribine Tablets
Brief summary
This study aims to describe participants characteristics that can predict the safety and effectiveness of cladribine tablets, as assessed by time-to-discontinuation of treatment with cladribine tablets, and to assess other patient-reported, clinical, and imaging outcomes in participants with relapsing multiple sclerosis (RMS) in the long term, in a real-world setting.
Interventions
DRUGMavenclad
This is an observational study, participants who received cladribine tablets in routine clinical practice following the SmPC will be included.
Sponsors
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult participants, male or female patients ≥ 18 years old at index date * Participants must voluntarily give written informed consent form (ICF). Patients must read and fully understand the ICF * Participants with confirmed diagnosis of RMS at index date, diagnosed by the treating physician according to applicable clinical practice guidelines (currently McDonald 2017 criteria), with high disease activity. * Required historical data should be available: number of relapses in the 12 months prior to index date, DMTs taken prior to index date, date of MS diagnosis, and data of at least 1 MRI prior to index date as specified in the drug Summary of Product Characteristics (SmPC) * Fulfillment of the indication for treatment with cladribine tablets at index date, per standard of care in accordance with the local SmPC * Meeting 1 of the following criteria: * Prospective participants: Having been prescribed with cladribine tablets or having taken at least one dose of cladribine tablets, with enrollment date prior to the second treatment week * Retrospective participants: Having taken at least one dose of cladribine tablets, with enrollment date during or after the second treatment week but not more than 3 years after the first dose of cladribine tablets
Exclusion criteria
* Contraindications to use of cladribine tablets according to the SmPC. * Any participant who had the first dose of cladribine tablets more than 3 years prior to enrollment * Any participant who is pregnant or plans to breast-feed while taking cladribine tablets, or any patient who or whose partner plans to become pregnant in Year 1 or within 6 months after the last dose in Year 2, or any participants who is unwilling or unable to use contraception per the SmPC * Have participated or participating in an interventional study since cladribine tablet initiation, in which participant assessment and/or treatment may be dictated by a protocol * Participants who, at the discretion of the Investigator, will not be able to provide reliable information for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to Discontinuation of Treatment with Cladribine tablets | Up to 48 months |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of participants Receiving Each of The Possible Number of Annual Treatment Courses with Cladribine Tablets | Baseline, 12 months, 24 months, 36 months and 48 months |
| Cumulative Cladribine Dose | Up to 48 months |
| Number of Relapses | Baseline, 12 months, 24 months, 36 months and 48 months |
| Proportion of Severe Relapses | Baseline, 12 months, 24 months, 36 months and 48 months |
| Percentage of Participants Free From Relapse | Year 2 and Year 4 |
| Time From Onset of Relapse to Recovery | Up to Month 48 |
| Annualized Relapse Rate (ARR) | At Year 2 and Year 4 |
| Percentage of Participants Free From Magnetic Resonance Imaging (MRI) Activity | At Year 1, Year 2, Year 3 and Year 4 |
| Percentage of Participants with Minimal MRI Activity (=< 2 New T2 Lesions) | At Year 1, Year 2, Year 3 and Year 4 |
| Timed 25-Foot Walk (T25FW) Score | Baseline, Year 1, Year 2, Year 3 and Year 4 |
| Percentage of Participants with an Increase and Decrease in Timed 25-Foot Walk (T25FW) Score of At Least 20% From Baseline at Year 1, 2, 3 and 4 | Baseline, Year 1, Year 2, Year 3 and Year 4 |
| 9-Hole Peg Test (9HPT) Score | Baseline, Year 1, Year 2, Year 3 and Year 4 |
| Percentage of Participants with an Increase and Decrease in 9-Hole Peg Test (9HPT) Score of At Least 20% From Baseline at Year 1, 2, 3 and 4 | Baseline, Year 1, Year 2, Year 3 and Year 4 |
| Percentage of Participants With Progressed, Improved, or Stable Disability as Assessed by Expanded Disability Status Scale (EDSS) Confirmed Over 6 Months | Year 1, Year 2, Year 3 and Year 4 |
| Percentage of Participants With Sustained Disability Progression, Improvement, or Stability Confirmed Over 6 Months as Assessed by T25FW Score | Year 1, Year 2, Year 3 and Year 4 |
| Percentage of Participants With Sustained Disability Progression, Improvement, or Stability Confirmed Over 6 Months as Assessed by 9HPT Score | Year 1, Year 2, Year 3 and Year 4 |
| Percentage of Participants With Minimal Evidence of Disease Activity (MEDA) | Year 2 and Year 4 |
| Percentage of Participants With No Evidence of Disease Activity (NEDA-3) | Year 2 and Year 4 |
| Multiple Sclerosis Impact Scale (MSIS-29) Physical Domain Score, Psychological Domain Score and Total Score | Baseline, Year 1, Year 2, Year 3 and Year 4 |
| EuroQol 5-Dimensions (EQ-5D-5L) Score | Baseline, Year 1, Year 2, Year 3 and Year 4 |
| Global Satisfaction, Effectiveness, Side Effects, and Convenience Domain Scores of Treatment Satisfaction Questionnaire for Medication (TSQM) | Baseline, Year 1, Year 2, Year 3 and Year 4 |
| Treatment Cost of Disease-Modifying Treatment (DMTs) | Up to 48 months |
| EuroQol Visual Analog Scale (EQ-VAS) Score | Baseline, Year 1, Year 2, Year 3 and Year 4 |
Countries
Belgium, Czechia, Greece, Netherlands, Poland, Portugal
Contacts
STUDY_DIRECTORMedical Responsible
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Outcome results
None listed